Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
5.07
-0.08 (-1.55%)
Yopilishda: May 12, 2026, 4:00 PM EDT
5.23
+0.16 (3.16%)
Bozordan keyin: May 12, 2026, 5:55 PM EDT
Lixte Biotechnology Holdings, Inc. - bu klinik bosqichdagi biofarmatsevtika va protonli saraton terapiyasi kompaniyasi bo'lib, saraton dorilari ishlab chiqish uchun maqsadlarni aniqlashga, shuningdek, saraton terapiyalarini ishlab chiqish va tijoratlashtirishga qaratilgan. Uning yetakchi mahsulot nomzodi, LB-100, mikrosatellit barqaror metastatik kolorektal saraton kasalligi bo'lgan bemorlar uchun Atezolizumab bilan birgalikda 1b-bosqichli klinik sinovlarda. Kompaniyaning LB-100 preparati doxorubicin bilan birgalikda rivojlangan yumshoq to'qimalar sarkomasi uchun 1b-bosqichda; va LB-100 dostarlimab bilan birgalikda tuxumdonning yorug' hujayrali karsinomasi uchun 1b/2-bosqichda. Kompaniya Niderlandiya Saraton Institutida klinik tadqiqotlar bo'yicha hamkorlik shartnomasiga ega; Ispaniya Sarkoma Guruhi bilan tadqiqotchi tashabbusli klinik sinov uchun hamkorlik shartnomasi; va Niderlandiya Saraton Instituti bilan hamkorlik bo'yicha rivojlanish shartnomasi. Lixte Biotechnology Holdings, Inc. 2005 yilda tashkil etilgan va Boca Raton, Florida shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Mr. Bastiaan van der Baan M.Sc. | Chief Scientific Officer |
| Mr. Geordan G. Pursglove | CEO, President & Chairman |
| Mr. Peter M. Stazzone | Chief Financial Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-17 | 8-K | form8-k.htm |
| 2026-03-31 | 10-K | form10-k.htm |
| 2026-03-20 | 8-K | form8-k.htm |
| 2026-03-10 | 8-K | form8-k.htm |
| 2026-02-18 | 8-K | form8-k.htm |
| 2025-12-31 | 8-K | form8-k.htm |
| 2025-12-23 | 8-K | form8-k.htm |
| 2025-12-22 | 8-K | form8-k.htm |
| 2025-12-11 | 8-K | form8-k.htm |
| 2025-11-25 | 8-K | form8-k.htm |